Document Detail

Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis.
MedLine Citation:
PMID:  17265505     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the effectiveness of methotrexate (MTX), which works not only as an immunosuppressant, but also as a potent antiinflammatory agent, as an alternative therapeutic option for patients with severe calcium pyrophosphate deposition disease (CPDD) who fail to respond to standard therapy with nonsteroidal antiinflammatory drugs and/or glucocorticoids. METHODS: We analyzed, in 2 university hospitals in Switzerland, consecutive patients with CPDD that was resistant to classic treatment and were subsequently treated with MTX. Before and after initiation of MTX therapy, we quantified the frequency of pseudogout attacks, pain intensity, the number of swollen and tender joints, and inflammatory biomarkers. Clinical and biologic side effects of MTX and patients satisfaction with MTX treatment were also evaluated. RESULTS: The study included 5 patients treated with low dosages of MTX (5-20 mg/week). The mean followup time with MTX was 50.4 months (range 6-81 months). All patients reported an excellent clinical response, with marked improvement within a mean period of 7.4 weeks. A significant decrease in pain intensity (P < 0.0001), swollen and tender joint counts (P < 0.0001), and frequency of attacks was observed. The biomarkers of inflammation decreased markedly when systematically analyzed (3 patients). No significant side effects were reported. CONCLUSION: This study suggests that MTX could be a valuable therapeutic option for severe CPDD that is refractory to conventional therapy.
Amélie Chollet-Janin; Axel Finckh; Jean Dudler; Pierre-André Guerne
Related Documents :
19035415 - Short-term improvement of endothelial function in rituximab-treated rheumatoid arthriti...
21367195 - 212 effect of consecutive superstimulatory treatment-induced follicular wave synchroniz...
20737185 - Successful treatment of steroid-resistant methotrexate-induced interstitial pneumonia w...
8835 - A long-term study of benorylate in patients with rheumatoid arthritis.
23206725 - Urinary incontinence and indwelling urinary catheters in acutely admitted elderly patie...
25402215 - The clinical indication and feasibility of the enhanced recovery protocol for curative ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  56     ISSN:  0004-3591     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-22     Completed Date:  2007-03-09     Revised Date:  2008-08-08    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  688-92     Citation Subset:  AIM; IM    
Division of Rheumatology, University Hospital of Geneva, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antirheumatic Agents / therapeutic use*
Chondrocalcinosis / drug therapy*,  physiopathology
Dose-Response Relationship, Drug
Glucocorticoids / therapeutic use
Methotrexate / therapeutic use*
Middle Aged
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antirheumatic Agents; 0/Glucocorticoids; 59-05-2/Methotrexate
Comment In:
Arthritis Rheum. 2008 Jul;58(7):2210-1   [PMID:  18576339 ]
Arthritis Rheum. 2007 Sep;56(9):3172   [PMID:  17763448 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in pat...
Next Document:  Kaposi sarcoma of the musculoskeletal system: a review of 66 patients.